Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313334 | 0.80 | CD44 (0.42) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL23040370 | 0.80 | TNKS (0.49) | TNKSTNKS2BACE1ALDH1A1TSHR | |
| SCHEMBL13349699 | 0.79 | TNKS (0.40) | TNKSTNKS2BACE1ALDH1A1CYP3A4 | |
| SCHEMBL2311209 | 0.78 | TRPA1 (0.51) | BACE1PTPN1ALOX5APFEN1 | |
| SCHEMBL2909376 | 0.77 | HSD17B10 (0.41) | TNKSTNKS2ALDH1A1CYP3A4TSHR | |
| SCHEMBL1337677 | 0.77 | FEN1 (0.47) | TNKSTNKS2BACE1ALDH1A1MAP4K4 | |
| SCHEMBL1918559 | 0.75 | ALDH1A1 (0.54) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL10987129 | 0.75 | ALDH1A1 (0.54) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL2815253 | 0.73 | ALDH1A1 (0.72) | ALDH1A1CYP3A4TSHRTDP1TP53 | |
| SCHEMBL28116695 | 0.73 | PTPRC (0.54) | TNKSTNKS2BACE1ALDH1A1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2349256-B1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-23 | — | — | EP | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| US-8232409-B2 | Heterocyclic benzimidazoles as TRPM8 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-31 | — | — | US | disclosed |
| EP-2349256-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | Janssen Pharmaceutica NV (BE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045166-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093788-A1 | HETEROCYCLIC BENZIMIDAZOLES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM6 | TNKS 1627/4885TNKS2 1916/4885BACE1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.